These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22218302)

  • 1. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.
    Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R
    Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.
    Wang L; Zhang Y; Zhao J; Xiao E; Lu J; Fu S; Wang Z
    Tumour Biol; 2014 Nov; 35(11):10879-90. PubMed ID: 25085582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
    Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
    Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell.
    He XD; Wang ZP; Wei HY; Zhou Q; Wang DG; Tian JQ; Fu SJ; Rodriguez R
    Urol Int; 2009; 82(2):209-13. PubMed ID: 19322012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
    Wang D; Wang Z; Tian J; He X; Chowdhury WH; Zhang X; Li S; Rodriguez R
    Urol Oncol; 2010; 28(2):164-9. PubMed ID: 18440837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
    Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R
    Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
    Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z
    Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice.
    Lu K; Wang F; Ma B; Cao W; Guo Q; Wang H; Rodriguez R; Wang Z
    Curr Gene Ther; 2021; 21(2):160-166. PubMed ID: 33334289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro.
    Shi J; Fu S; Wang L; Tao Y; Rodriguez R; Wang Z
    Anticancer Drugs; 2017 Jan; 28(1):88-96. PubMed ID: 27622605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
    Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
    Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
    Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
    Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
    Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
    Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.